Subscribe
emiliaungur-shutterstock-com
EmiliaUngur / Shutterstock.com
17 August 2015Americas

FFC claims Allergan’s complaint violates anti-SLAPP laws

US hedge fund Ferrum Ferro Capital (FFC) has asked a California court to reject Allergan’s complaint about malicious prosecution because it allegedly violates a state law designed to stop parties from intentionally burdening another party with a legal complaint.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Allergan survives Combigan patent challenge
29 September 2015   Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Allergan survives Combigan patent challenge
29 September 2015   Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review.

More on this story

Americas
Allergan survives Combigan patent challenge
29 September 2015   Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review.

More features

Gene tech firm fends off injunction in test kit dispute
Comparing life sciences IP in Brazil and the US
Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal